TriSalus Life Sciences (NASDAQ: TLSI) — Perfil da empresa, notícias e dados financeiros
TriSalus Life Sciences focuses on innovative drug delivery solutions for solid tumors, improving outcomes in cancer treatment.
TriSalus Life Sciences
TriSalus Life Sciences (NASDAQ:TLSI) is a pioneering biotechnology firm committed to transforming the treatment of solid tumors through integrated therapeutic and drug delivery solutions. Focusing on innovative research and development, TriSalus is dedicated to advancing technologies that enhance the delivery of immunotherapies and drugs directly to the site of disease, especially targeting liver and pancreatic cancers. The company's projects include developing proprietary Pressure-Enabled Drug Delivery (PEDD) technology and SD-101, an immunotherapy agent, aiming to improve outcomes for patients battling these hard-to-treat cancers. TriSalus's objective is to overcome the limitations of current treatments by enhancing drug concentrations at the tumor site, thereby improving therapeutic efficacy and patient survival rates.
Resumo
Operações
Produtos e/ou serviços de TriSalus Life Sciences
- Pressure-Enabled Drug Delivery (PEDD) technology aims to improve the delivery of therapeutics to solid tumors.
- SD-101, an investigational Toll-like receptor 9 (TLR9) agonist for treating solid tumors.
- Immunotherapy programs focus on leveraging the immune system to fight cancer, particularly in the liver and pancreas.
- Drug development portfolio targeting diseases with high unmet medical need, focusing on oncology and liver diseases.
- Life sciences research collaborations aimed at discovering and advancing innovative treatments for cancer.
- Technology platforms designed to enhance the administration and effectiveness of oncology therapies.
equipe executiva do TriSalus Life Sciences
- Mary T. SzelaCEO, President & Director
- David B. PatienceChief Financial Officer
- Richard B. MarshakChief Commercial Officer
- Andrea MarassoVice President of Marketing
- Jennifer L. StevensChief Regulatory, Quality and Therapeutics Officer
- Bryan F. CoxChief of Research
- Richard MarshallChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela TriSalus Life Sciences, em USD.
- Cap. de mercado
- 242 mi
- Receita (TTM)
- 45,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- -62.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 45,2 mi | -26,9 mi | -39,2 mi | |
| 29,4 mi | -36,2 mi | -33,2 mi | |
| 18,5 mi | -54,5 mi | -59,4 mi | |
| 12,4 mi | -36,4 mi | -47,2 mi |